Real-world use of quetiapine in early psychosis: An acute inpatient and community follow-up effectiveness study

International Journal of Psychiatry in Clinical Practice

Volumn 12, Issue 1, 2008, Pages 65-73

  Victor Catts, Stanley ^a,b   Desmond James Frost, Aaron ^b   Gifford, Shaune ^b   Scott, James ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Acute care; Atypical antipsychotic; Consent; First episode psychosis; Response prediction; Substance abuse

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; DIAZEPAM; LITHIUM; MOOD STABILIZER; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ACUTE DISEASE; ADJUVANT THERAPY; ADOLESCENT; ADULT; AGITATION; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMMUNITY; DISEASE SEVERITY; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; MALE; MENTAL DISEASE; OPEN STUDY; ORTHOSTATIC HYPOTENSION; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SIDE EFFECT; SUBSTANCE ABUSE; TREATMENT FAILURE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 45849083456     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500701496733     Document Type: Article

References (36)

1. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews 2004;2:DOI 10.1002/14651858.CD000967. pub2.
2. Hatim A, Habil H, Jesjeet SG, et al. Safety and efficacy of rapid dose administration of quetiapine in bipolar mania. Hum Psychopharmacol 2006;21:313-8.
3. Pini S, Abelli M, Cassano GB. The role of quetiapine in the treatment of bipolar disorder. Exp Opin Pharmacother 2006;7:929-40.
4. Calabrese JR, Keck PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-60.
5. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001;23:1839-54.
6. Kasper S. Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety 2004;20:44-7.
7. Hirscheld RMA, Weisler RH, Raines SR, Macfadden W. Quetiapine in the treatment of anxiety in patients with bipolar I and II depression: A secondary analysis from a randomised double-blind placebo-controlled study. J Clin Psychiatry 2006;67:355-62.
8. Chengappa KNR, Goldstein JM, Greenwood M, John V, Levine J. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther 2003;25:530-41.
9. Arango C, Bernardo M. The effect of quetiapine on aggression and hostility in patients with schizophrenia. Hum Psychopharmacol 2005;20:237-41.
10. Remington G. Rational pharmacotherapy in early psychosis. Br J Psychiatry 2005;187(Suppl 48):77-84.
11. Tauscher-Wisnieski S, Kapur S, Tauscher J, et al. Quetiapine: An effective antipsychotic in first episode schizophrenia despite only transient high dopamine-2 receptor blockade. J Clin Psychiatry 2002;63:992-7.
12. Rummel C, Kissling HJ, Leucht S. New generation antipsychotics for first episode schizophrenia. Cochrane Database of Systematic Reviews 2003;4: DOI 10.1002/14651858.CD004410.
13. Feetam C, Donoghue J. Antipsychotics in the treatment of first-episode schizophrenia. Pharm J 2003;/270:/405-8.
14. Potvin S, Pamoulova T, Mancini-Marie A, Lipp O, Bouchard RH, Stip E. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiatry 2006;77:796-8.
15. Taylor D, Mace S, Mir S, Kerwin R. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psychiatry Clin Pract 2000;4:41-6.
16. Mladsi DM, Grogg AL, Irish WD, et al. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. Curr Med Res Opin 2004;20:1883-93.
17. Lambert M, Conus P, Schimmelmann BG, et al. Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: Results of an open retrospective medical record study. Pharmacopsychiatry 2005;38:206-13.
18. Citrome L, Jaffe A, Levine J, Lindenmayer J-P. Dosing of quetiapine in schizophrenia: How clinical practice differs from registration studies. J Clin Psychiatry 2005;66:1512-6.
19. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2004;14:372-94.
20. International Early Psychosis Association Writing Group. International clinical practice guidelines for early psychosis. Br J Psychiatry 2005;187(Suppl. 48):s120-4.
21. Potkin SG, Gharabawi GM, Greenspan AJ, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006;85:254-65.
22. Overall JE, Gorham DR. Brief psychiatric rating scale. Psychol Rep 1962;10:799-912.
23. Kay S. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
24. Schutte NS, Malouff JM. Measures of global functioning. In: Schutte NS, Malouff JM, editors. Sourcebook of adult assessment strategies. New York: Plenum Press; 1995. p 461.
25. Simpson GM, Angus JWS. A rating scale for extrapyramidal side-effects. Acta Psychiatr Scand 1970;212(Suppl 44):11-9.
26. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6.
27. Guy W. In: ECDEU Assessment Manual for Psychopharmacology, revised edition. Washington DC, US Department of Health Education and Welfare. Publication (ADM) 76-338; 1976. p 534.
28. Kopola LC, Good KP, Milliken H, et al. Treatment of a first episode of psychotic illness with quetiapine: An analysis of 2 year outcomes. Schizophr Res 2006;81:29-39.
29. O'Toole M, Taylor T, Walters J, Ohson R, Purvis L, Pilowsky. The Southwark First Onset Psychosis Service (FIRST): A longitudinal prospective follow-up study of quetiapine treatment in first-episode schizophrenia. Schizophr Res 2003;60(Suppl):327.
30. Stigler K, Potenza MN, Posey DJ, McDougle CJ. Weight gain associated with atypical antipsychotic use in children and adolescents. Pediatr Drugs 2004;6:33-44.
31. Larsen TK, Melle I, Auestad B, et al. Substance abuse in first-episode non-affective psychosis. Schizophr Res 2006;88:55-62.
32. McEvoy JP, Lieberman JA, Perkins D, Hamer RM. Comparison of Atypicals in First-Episode psychosis (CAFE): A randomised 52-week comparison of olanzapine, quetiapine, and risperidone. Neuropsychopharmacol 2005;30(Suppl):s201.
33. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003;160:2063-5.
34. Gasquet I, Haro JM, Novick D, et al. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int J Clin Psychopharmacol 2005;20:199-205.
35. Addington J, Mansley C, Addington D. Weight gain in first-episode psychosis. Can J Psychiatry 2003;48:272-6.
36. Catts SV, Carr VJ, O'Toole BI, et al. Variance components model predicting outcome in a multi-site multi-level study of early psychosis treatment. Schizophr Bull 2007;33:584-5.